Crossmark

High HIV viral suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis of programmatic evidence

Crossref DOI link: https://doi.org/10.1186/s12981-025-00788-8

Published Online: 2025-09-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Girón-Callejas, Amalia

Lorenzana, Rolando

Pickles, Michael

Inzaule, Seth

Jordan, Michael R.

Diaz, Sheilee

Vrinten, Charlotte
Funding

Funding for this research was provided by:

Medical Research Council (MR/X020258/1)

U.S. National Institutes of Health (NIH UM1 AI068617)
License Information

Text and Data Mining valid from 2025-09-26

Version of Record valid from 2025-09-26
More Information

Article History

Received: 12 May 2025

Accepted: 11 August 2025

First Online: 26 September 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below